Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Jumps 4.9% – Here’s What Happened

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price shot up 4.9% on Monday. The company traded as high as $22.1350 and last traded at $22.1350. 115 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 1,668 shares. The stock had previously closed at $21.10.

Wall Street Analyst Weigh In

HKMPF has been the topic of several recent analyst reports. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. Barclays raised shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Stock Up 5.1%

The company has a 50-day moving average price of $21.76 and a 200 day moving average price of $20.28.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company that develops, manufactures and markets a broad range of medicines. Its portfolio includes generic, branded and specialty products, as well as injectable medicines used in hospitals and other healthcare settings. The company serves areas such as respiratory, pain management, anti-infective, oncology and cardiovascular care.

Hikma operates through three principal businesses: Injectables, Generics and Branded Medicines. Its injectables business supplies a range of products to hospitals and healthcare providers, while its generics business focuses on prescription medicines, including complex products.